BOARD OF DIRECTORS

Non Executive Members

Adele C. Oliva

Adele Oliva is a Partner at Quaker BioVentures
(www.quakerbio.com), a venture capital firm dedicated to investing in life science companies located in the Mid-Atlantic region and contiguous states. She joined Quaker in June 2007. Previously, Adele was a Partner at Apax Partners which she had joined in 1997 following her selection as a Ewing Marion Kauffman Fellow in Venture Capital and Entrepreneurship. At Apax, she co-led the Healthcare Group in the United States with a focus on specialty pharmaceuticals and medical devices/products. Prior to Apax, she held positions in marketing and business development with Baxter Healthcare in the company's Cardiovascular and I.V. Systems divisions. Adele's experience also includes positions with Ogilvy & Maher, where she was employed in the firm's office in Hungary, and with CoreStates Financial Corp., where she worked as a commercial lending officer and senior financial analyst. In addition to EKR Therapeutics, her experience as a Board member includes Prometheus Labs, SkinMedica, Esprit Pharma, Alliance Healthcare Solutions, ESP Pharma., and Xanodyne Pharmaceuticals. Adele is a graduate of Saint Joseph's University and earned an M.B.A. in Marketing from Cornell University, where she was awarded a Fried Fellowship.

Zev S. Scherl

Zev Scherl is a General Partner at NewSpring Capital (www.newspringcapital.com), a family of private equity funds focused on the Mid-Atlantic region. He possesses significant experience in principal investing, corporate management and finance, focused exclusively in the life sciences and health care industries. Prior to NewSpring, he worked at Pequot Ventures where he orchestrated investments in emerging life sciences and health care companies. Previously, he was a member of the health care investment team of Behrman Capital where he originated, executed and actively managed health care investments. Before entering private equity in 1997, Zev served as Senior Director, Strategic Planning, for Value Health, the largest independent pharmacy and mental health benefit management company. He also served as U.S. Manager, Pricing Policy at Merck & Co., and prior to that was in the investment banking group at Lehman Brothers. In addition to serving as a Director for EKR Therapeutics, Mr. Scherl is currently a board member for AppTec Laboratory Services, Scandius BioMedical, Inc., Nitric BioTherapeutics, and Immune Control, Inc. He received a B.A degree with honors in economics from Duke University and an M.B.A. from Harvard Business School.

S. Douglas Sheldon

S. Douglas. Sheldon is a co-founder and Managing Partner of ESP Equity Partners, LLC (www.espequity.com), a private equity fund with offices in New Jersey, Beijing and Bangkok. Previously, in 2000, Mr. Sheldon co-founded ESP Partners LLC, the predecessor to ESP Pharma, a specialty pharmaceutical company acquired by PDL BioPharma in 2005. He has over 30 years of pharmaceutical and related healthcare experience, both internationally and domestically, including having served as Vice-President of Strategic Partnership Development at Parke-Davis Pharmaceuticals. Doug began his career with Pfizer, Inc. where he served nearly 17 years in senior international finance, marketing, country management, and regional line management assignments in South America and Asia. He left Pfizer in 1991 to form TTMC, Ltd, a venture company focused on healthcare and life sciences businesses in South East Asia. Later, in 1994 he founded the Indochina Healthcare Ltd (IHL) joint venture operations in Thailand, Hong Kong, Vietnam and Myanmar, merging TTMC's hospital products business in orthopedics and urology with the oncology and cardiovascular business of Mayne Pharma (formerly F.H. Faulding, Australia). Today, he continues to actively serve as an Executive Director and Chairman of IHL. Mr. Sheldon, who is also fluent in Spanish, received his B.S. in Chemistry from LeMoyne College and M.B.A. in Finance and Marketing from Syracuse University.